ACET Share Price | Adicet Bio, Inc. Stock Analysis & Recommendation

Q: What does Adicet Bio, Inc. do?

Overview:Adicet Bio, Inc. is a biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -28 Million (Quarterly Results - Mar 2025) Market cap: USD 55.61 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.91 Return on Equity: -72.67% Price to Book: 0.34Contact Details:Address: 500 Boylston St Fl 12, BOSTON MA: 02116-3740 Tel: 1 617 4822333 Fax: 1 302 6555049 Website: https://www.adicetbio.com/

Q: Who are in the management team of Adicet Bio, Inc.?

As of March 2022, the management team of Adicet Bio, Inc. includes Mr. Chen Schor, who serves as the President, Chief Executive Officer, Secretary, and Director. Additionally, the Board of Directors consists of Mr. Erez Chimovits, Mr. Steve Dubin, Mr. Carl Gordon, Dr. Aya Jakobovits, and Dr. Bastiano Sanna, all of whom hold the designation of Director.

Q: Is Adicet Bio, Inc. overvalued or undervalued?

As of 9 May 2023, the valuation grade for Adicet Bio, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued, as evidenced by its price-to-book value of 0.39 and an EV to EBITDA ratio of 0.71, which are not favorable compared to its peers. Notably, Adicet's return on equity (ROE) stands at a concerning -72.67%, highlighting the challenges it faces in generating returns for shareholders.In comparison to its peers, such as ADC Therapeutics SA, which is rated risky with an EV to EBITDA of -4.8904, and Kinnate Biopharma, Inc., which is rated fair with an EV to EBITDA of 0.2381, Adicet's metrics suggest it is lagging behind in terms of financial health. The company's recent stock performance has also been poor, with a year-to-date return of -34.01%, significantly underperforming the S&P 500's 2.44% return. This combination of unfavorable ratios and weak market performance reinforces the conclusion that Adicet Bio, Inc. is overvalued at its current price of 0.63.

Q: Is Adicet Bio, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Adicet Bio, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating bearishness and monthly Bollinger Bands showing a mildly bearish trend. Although the weekly MACD is mildly bullish, the overall indicators suggest weakness. The stock has underperformed significantly compared to the S&P 500, with a 1-year return of -44.49% versus the S&P 500's 17.14%, reflecting a challenging environment for the stock.

Results Declared: Adicet Bio, Inc. has declared results on 12 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

23.89 k

Shareholding (Dec 2025)

FII

7.62%

Held by 38 FIIs

DII

69.72%

Held by 10 DIIs

Promoter

13.53%

How big is Adicet Bio, Inc.?

22-Jun-2025

As of Jun 18, Adicet Bio, Inc. has a market capitalization of 55.61 million and reported net sales of 0.00 million, with a net profit of -117.32 million over the latest four quarters. Shareholder's funds are 186.61 million, and total assets amount to 220.22 million.

View full answer

What does Adicet Bio, Inc. do?

22-Jun-2025

Adicet Bio, Inc. is a biotechnology company developing allogeneic gamma delta T cell therapies for cancer and other diseases, classified as a micro-cap with a market cap of $55.61 million. As of March 2025, it reported a net profit loss of $28 million and has no dividend yield.

View full answer

Who are in the management team of Adicet Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Adicet Bio, Inc. is led by Mr. Chen Schor as President and CEO, with a Board of Directors that includes Mr. Erez Chimovits, Mr. Steve Dubin, Mr. Carl Gordon, Dr. Aya Jakobovits, and Dr. Bastiano Sanna.

View full answer

Is Adicet Bio, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2023, Adicet Bio, Inc. is considered overvalued with a valuation grade of "does not qualify," reflecting poor financial metrics such as a -72.67% return on equity and a year-to-date stock performance of -34.01%, significantly underperforming its peers and the S&P 500.

View full answer

Is Adicet Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Adicet Bio, Inc. is in a mildly bearish trend, indicated by daily moving averages and monthly Bollinger Bands, with a significant 1-year return of -44.49% compared to the S&P 500's 17.14%.

View full answer

Compare Adicet Bio, Inc. with Similar Stocks

Xilio Therapeutics, Inc.Outlook Therapeutics, Inc.Clene, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 69 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-105.38%

Price to Book

0.63

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-31 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-18.02%

6 Months

-50.2%

1 Year

-53.45%

2 Years

-80.57%

3 Years

-92.77%

4 Years

-97.51%

5 Years

-96.87%

Adicet Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-175.41%

EBIT to Interest (avg)

-87.31

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.91

Sales to Capital Employed (avg)

0.08

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

83.83%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.63

EV to EBIT

0.26

EV to EBITDA

0.27

EV to Capital Employed

-3.33

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-105.38%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 23 Schemes (9.13%)

Foreign Institutions

Held by 38 Foreign Institutions (7.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -13.38% vs 13.78% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.40",
          "val2": "-26.40",
          "chgp": "-15.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.50",
          "val2": "-26.90",
          "chgp": "-13.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.26% vs 17.94% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-115.70",
          "val2": "-121.10",
          "chgp": "4.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-116.80",
          "val2": "-117.10",
          "chgp": "0.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-30.40

-26.40

-15.15%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-30.50

-26.90

-13.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -13.38% vs 13.78% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-115.70

-121.10

4.46%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-116.80

-117.10

0.26%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 0.26% vs 17.94% in Dec 2024

All Annual Results

Company CV

About Adicet Bio, Inc.

Adicet Bio, Inc.

Pharmaceuticals & Biotechnology

Adicet Bio Inc., formerly resTORbio, Inc., is a biotechnology company. The Company is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.

Company Coordinates

Company Details

500 Boylston St Fl 12 , BOSTON MA : 02116-3740

Tel: 1 617 4822333

https://www.adicetbio.com/

Registrar Details